QuidelOrtho to Announce Second Quarter 2022 Financial Results


SAN DIEGO, July 18 10, 2022 (GLOBE NEWSWIRE) — QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a leading in vitro diagnostics company, today announced that it will report financial results for its second quarter 2022 ended July 3, 2022, after market close on Thursday August 4, 2022.

Following the release of financial results, QuidelOrtho will host a conference call beginning at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss the financial results. Interested parties can access the conference call in the “Events and Presentations” section of the “Investor Relations” page of QuidelOrtho’s website at https://ir.quidelortho.com/. Those unable to access the webcast can join the call by phone by dialing 844-200-6205 (domestic) or 929-526-1599 (international) and entering conference ID 525922.

A replay of the conference call will be available shortly after the event on the “Investor Relations” page of QuidelOrtho’s website, under the “Events & Presentations” section.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission to develop and manufacture innovative technologies that increase diagnostic test performance and create better patient outcomes in the across the healthcare continuum.

Ranked among the largest in the world in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine leading expertise in immunoassays and molecular testing with a global presence in clinical laboratories and transfusion medicine.

Our company’s comprehensive product portfolio delivers accuracy, speed, automation and access, delivering critical information when and where it’s needed most. Inspired by a spirit of service, the QuidelOrtho family is committed to improving the well-being of people around the world and is happy to know that we are making a difference. www.quidelortho.com

Investor contacts:
Bryan Brokmeier, CFA

Media Contact:


Comments are closed.